The Bottom Line for Pharma: Expect the Unexpected
The Centers for Medicare & Medicaid Services (CMS) recently unveiled its list of 10 drugs up for the first price negotiations under the Inflation Reduction Act (IRA). The drugs that made the price negotiation cut are Johnson & Johnson’s Imbruvica, Stelara, and Xarelto, plus Bristol Myers Squibb’s Eliquis, Merck & Co.’s Januvia, Novartis’ Entresto, Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Novo Nordisk’s Fiasp, and Amgen’s Enbrel. Valuate Health Consultancy (Valuate) has compiled five essential takeaways as pharma navigates the Medicare price negotiation process. Download the PDF for more information.
Valuate has a proven track record of helping biopharmaceutical clients communicate clinical and economic value to payers before approval. Contact us today if you have additional questions about the implications of the IRA.
Archbow Consulting, Entrée Health, and Valuate Health Consultancy are sister companies under the Value and Access division of Omnicom Health Group. Learn more about our united organizations here.
Related Blog Posts:
Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe reach their commercial goals with strategic and tactical approaches to distribution, pharmacy, and patient access. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn, Twitter or subscribing to this blog which you can do below.